TScan Therapeutics (TCRX) Invested Capital (2023 - 2026)
TScan Therapeutics (TCRX) posted quarterly Invested Capital of $10.3 million for Q2 2024, up 52.07% quarter-over-quarter from $6.8 million in Q1 2024.
TScan Therapeutics (TCRX) Invested Capital (2023 - 2026) Analysis & Trends
TScan Therapeutics (TCRX) has reported Invested Capital for 2 consecutive years, with $10.3 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Invested Capital changed N/A year-over-year to $10.3 million; the TTM figure through Mar 2025 stood at $10.3 million (down 8.16% YoY), while the FY2023 annual figure was $3.3 million, changed N/A from the prior year.
- Invested Capital advanced to $10.3 million in Q2 2024 per TCRX's latest filing, from $6.8 million in the prior quarter.
- Across five years, Invested Capital topped out at $10.3 million in Q2 2024 and bottomed at $1.1 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | TScan Therapeutics | 100.62 Mn | 100.62 Mn | - | 11.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.71 Mn |
| Jun 30, 2024 | 10.34 Mn |
| Mar 31, 2024 | 6.80 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 1.11 Mn |